title: [A sero-epidemiologiecal study on hepatitis B among general population in Beijing].
abstract: OBJECTIVE
  To explore the serological infection rate of hepatitis B virus (HBV) in general population aged over one year old in Beijing and to provide information for control and prevention of the disease.
  
  
  METHODS
  A multistage randomized cluster sampling was carried out in general population of Beijing, aged over one year old. Every study subject's hepatitis B immunization history and main risk factors were investigated through questionnaire. Venous blood samples were collected and then tested for five hepatitis B serological antigens and antibodies by means of Abbott Microparticle Enzyme Immunoassy method.
  
  
  RESULTS
  The prevalence rates of HBsAg, anti-HBs, anti-HBc and total HBV infection rate were 3.49% (95% CI:2.99-3.99), 37.79% (95% CI: 36.46-39.12), 35.04% (95% CI: 33.72-36.35) and 35.09% (33.78-36.40) respectively. The age standardized rates were 3.02% ,42.47% ,26.86% and 26.90% respectively.
  
  
  CONCLUSIONS
  Achievement in hepatitis B control and prevention was made in Beijing since the prevalence rate of hepatitis B surface antigen had been below 1% for children aged less than 5 years old. As for the general population, the prevalence rate of hepatitis B surface antigen had reduced to
authors.affiliation: Beijing Center for Disease Control and Prevention, Beijing 100013, China.
authors.forename: Jiang
authors.initials: J
authors.lastname: Wu
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Li-li
authors.initials: LL
authors.lastname: Han
authors.forename: Chang-ying
authors.initials: CY
authors.lastname: Lin
authors.forename: Hui
authors.initials: H
authors.lastname: Lin
authors.forename: Yu-lan
authors.initials: YL
authors.lastname: Xing
authors.forename: Pei
authors.initials: P
authors.lastname: Gao
authors.forename: Xiao-hong
authors.initials: XH
authors.lastname: Gong
authors.forename: Li-rong
authors.initials: LR
authors.lastname: Liu
authors.forename: Fang
authors.initials: F
authors.lastname: Huang
authors.forename: Jian-ying
authors.initials: JY
authors.lastname: Liu
authors.forename: Li-ying
authors.initials: LY
authors.lastname: Liu
authors.forename: Hua-yong
authors.initials: HY
authors.lastname: Wang
authors.forename: Hai-zhu
authors.initials: HZ
authors.lastname: Yu
authors.forename: Xiu-jun
authors.initials: XJ
authors.lastname: Liu
authors.forename: Ya-qing
authors.initials: YQ
authors.lastname: Tang
authors.forename: Yong-lan
authors.initials: YL
authors.lastname: Pu
authors.forename: Wei
authors.initials: W
authors.lastname: Zhao
authors.forename: Chen
authors.initials: C
authors.lastname: Wang
authors.forename: Zhen
authors.initials: Z
authors.lastname: Zhang
authors.forename: Li-xian
authors.initials: LX
authors.lastname: Ma
mesh_terms: D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D002648:Child; D002675:Child, Preschool; D002681:China / Q000453:epidemiology; D006509:Hepatitis B / Q000097:blood* / Q000453:epidemiology* / Q000276:immunology / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000276:immunology; D006514:Hepatitis B Surface Antigens / Q000276:immunology; D017325:Hepatitis B Vaccines / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008875:Middle Aged; D055815:Young Adult
chemical_list: D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D017325:Hepatitis B Vaccines